Animal testing is used in pharmaceutical and industrial research to predict human toxicity, and yet analysis suggests that animal models are poor predictors of drug safety in humans. The cost of animal research is high-in dollars, delays in drug approval, and in the loss of potentially beneficial drugs for human use. Human subjects have been harmed in the clinical testing of drugs that were deemed safe by animal studies. Increasingly, investigators are questioning the scientific merit of animal research. This review discusses issues in using animals to predict human toxicity in pharmaceutical develop- 
T
here is no doubt that the use of animals in science and medicine has significantly benefitted human beings (Table 1) . However, many investigators are increasingly concerned that animal experimentation may be based on a scientifically flawed premise and that it retains its acceptability only because clear alternatives have not been identified. Dramatically rising costs and extremely high failure rates in drug development have led many to re-evaluate the value of animal studies.
This review focuses on questions regarding the scientific validity of nonhuman animal models (hereafter referred to simply as "animal research") in predicting human toxicity in preclinical pharmaceutical testing.
HISTORICAL PERSPECTIVE
In the United States, the use of animals to test human were contradicted in humans and only 37% were ever replicated in humans (10). A review of 221 animal experiments found agreement in human studies just 50% of the time-essentially randomly (11) . Review of 37 chemicals studied in the U.S. National Toxicology Program concluded that toxicities other than carcinogenesis were not reproducible between rats and mice, between sexes, or compared with historic control animals. Average positive predictive value (PPV) from mouse to rat was 55.3% and 44.8% for long-term and short-term studies, respectively. Combining organ, length of exposure, and sex, PPV between mice and rats hovered around 50%, which is no greater than random chance (12) . An analysis of 2,366 drugs concluded that "results from tests on animals (specifically rat, mouse and rabbit models) are highly inconsistent predictors of toxic responses in humans, and are little better than what would result merely by chance-or tossing a coin-in providing a basis to decide whether a compound should proceed to testing in humans" (13) . Similar results were found for nonhuman primates and dogs (14) . Indeed, we need go no farther than the failure rates in drug development to have serious questions about whether animal testing accurately predicts toxicity in human trials.
About 12% of pharmaceuticals pass preclinical testing to enter clinical trials (15) . Of those, only 60% successfully complete phase I trials (16) . Overall, approximately 89% of novel drugs fail human clinical trials, with approximately one-half of those failures due to unanticipated human toxicity ( Figure 1 ) (17) . If animal tests accurately predict human toxicity, then why are toxicity-related failure rates in human clinical trials so high?
THE PRICE OF WRONG DECISIONS
Two critical "wrong" decisions regarding animal tests of human pharmaceuticals are 1) falsely identifying a toxic drug as "safe" and 2) falsely labeling a potentially useful therapeutic agent as toxic.
When a human-toxic drug is identified as "safe" by animal testing, the most likely outcome by far is that the drug will fail in clinical testing, often due to unacceptable adverse human effects, and sometimes significantly harming volunteer research subjects in the process. Drugs that survive clinical trials and attain market approval may still be recalled later due to toxicity identified only after months or years of inhuman use. Vioxx (Merck, Kenilworth, New Jersey) was found after release to significantly increase the risk of cardiovascular morbidity and mortality, costing Merck more than $8.5 billion in legal settlements alone (18) . An estimated 88,000 people suffered heart attacks after taking Vioxx and 38,000 died (19) .
Of 578 discontinued and withdrawn drugs in Europe and the United States, almost one-half were withdrawn or discontinued in post-approval actions due toxicity (20) . Van Meer et al. (21) found that of Protein-based biologics (e.g., monoclonal antibodies), fusion proteins, and recombinant proteins now account for most development stage and marketed biopharmaceuticals (15) . These present a particular challenge in predicting human toxicity, due to their propensity to provoke production of antidrug antibodies. Safety concerns include cross reactivity, potentially exaggerated pharmacology, and slow recovery from toxicity, among others (15, 24) -and immunogenic responses in animals do not predict immunogenicity in humans (15, (25) (26) (27) .
There are many notable examples of cases in which animal trials did not predict severe human toxicity.
Isuprel for treatment of asthma caused over 3,500 deaths in Great Britain alone, despite safety in rats, guinea pigs, dog, and monkeys, all of which had received doses far exceeding those administered in humans (2, 28) . Thalidomide caused devastating phocomelia in an estimated 20,000 to 30,000 infants before it was withdrawn. However, animal tests failed to reveal significant teratogenicity in 10 strains of rats; 11 breeds of rabbit; 2 breeds of dog; 3 strains of and been lost to patients, even though they would have been both safe and effective (36, 37) . Because a drug that shows toxicity in animal models is unlikely to ever undergo human testing, the magnitude of this type of "error" is unknown. However, many highly beneficial drugs would have failed animal testing and would never have been brought to market, except that they were developed before animal testing was required (38) . Examples include penicillin (fatal to guinea pigs) (39) , paracetamol (toxic in dogs and cats) (40) , and aspirin (embryo toxicity in rats and rhesus monkeys) (41) . Predictive models for human diseases and their processes
Predictive models for testing drugs and other chemicals for human toxicity and efficacy "Spare parts"-e.g., pig-derived aortic valve prostheses
Bioreactors or factories-e.g., production of monoclonal antibodies
Sources of tissue to study physiological principles
Educational "material" to educate and train biology and medical students and others
Subjects in research to benefit other animals Subjects of research to gain basic knowledge for its own sake approximately 56%.
Animal Research and Human Pharmaceutical Toxicity to complete all required animal studies to register a single pesticide (43) . Compared with the costs of in vitro testing, animal tests range from 1.5Â to >30Â
as expensive (44, 45) .
No comprehensive reviews of the total overall cost of animal testing in pharmaceutical development appear to exist. In part, this may be because even the total number of animals or of such studies is unknown. The 2002 amendments to the Animal Welfare Act exempted mice, rats, fish, and birds used in animal research from required reporting to the U.S.
Department of Agriculture (46) . These are the 4 most common types of animals used, and they account for >90% of all U.S. animal subjects and 81% of European animal subjects (45, 47) .
Costs of animal toxicity tests can be estimated from other industries, however, and are eye-opening.
According to the Organization for Economic Development, which determines animal testing guidelines and methodology for government, industry, and independent laboratories in its several dozen member countries, the average cost of a single, 
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Animal Research and Human Pharmaceutical Toxicity likelihood of false negative results. Once a drug tests positive for toxicity in animals, it is rarely tested against humans, and the prevalence of the real condition the test is being used to "detect"-human toxicity-remains unknown.
However, the "value" of using a given test to improve the post-test probability of ruling in or ruling out a condition can be calculated using likelihood ratios even if the prevalence of the condition is unknown, so long as the sensitivity and specificity of the test are known. LR are indicators of whether the results of a given test will "add weight" over the pretest probabilities (i.e., prevalence rate) of the condition in deciding what the probability is that a condition is actually present or absent.
There are 2 types of LR: the positive likelihood ratio (PLR) indicates how much more likely it is that a condition exists after a positive test result, when compared with its pre-test probability. The negative likelihood ratio (NLR) indicates how much the probability that a condition exists decreases compared with its pre-test probability, given a negative test result.
The change in post-test probability from pre-test probability is calculated by multiplying the pre-test probability (prevalence) by the PLR or NLR. If the change in post-test probability from the pre-test probability is small (i.e., LR, the multiplier, is small), then the test is unlikely to help determine the presence or absence of a condition over simply knowing its prevalence. LR of <1.0 actually indicate a negative shift in post-test probabilities. In other words, if a PLR is <1.0, then for any subject that has a positive test result, the probability that they have the condition decreases compared with the pre-test probability. For an NLR of <1.0, for any subject with a negative test, the probability that they do not have the condition also decreases compared with the pre-test probability. For an LR of 1.0, there is no change from pre-test probabilities (pre-test probabilities are simply multiplied by 1), and the test also was not useful. For LR >1.0, the probability of the condition being present increases in the face of a positive test, and the probability of the condition being absent increases in the presence of a negative test. For LR from 1.0 to 10, these changes are relatively small (meaning the test will not add much), but for LR >10, the changes increase exponentially and are considered significant (51-54).
Using LR to calculate the probability that a test will improve detection of a condition or ruling it out is complex; it requires knowing the sensitivity and specificity of a test and pre-test probabilities, conversion of probabilities to odds and back again, and then using a log table (i.e., a Fagan's nomogram) or log calculator to determine how much a test is likely to improve (or decrease) the chances of detecting the condition (53).
LR are increasingly being used to express translatability of animal toxicity testing (52-55). Bailey et al. (14) found that the presence of toxicity in a species sometimes added evidentiary weight to the risk of toxicity in another, but the reverse was not true: negative toxicity tests in animals did not significantly increase the probability that a toxic test would also be negative in humans, and a lack of toxicity in any species would not reliably indicate a Animal Research and Human Pharmaceutical Toxicity probable lack of toxicity in any other species, including comparisons of primate to human toxicity tests (14) . Furthermore, even in the presence of animal toxicity, LRs were extremely inconsistent and varied considerably for different classes of drugs (13, 52) . Similar findings have been reported in multiple analyses and reviews in other studies (52, (54) (55) (56) .
A number of studies have reviewed LR of specific drug toxicity tests for which both animal and human data are available. In a review of 2,366 drugs, including data from 3 of the most common animal research species-rat, mouse, and rabbit-PLRs were generally high (i.e., there is a likelihood that positive toxicity tests in animals would show toxicity in humans). But median NLRs were very low-1.12 (rabbit), 1.39 (mouse), and 1.82 (rat); in other words, they
were of little or no value in excluding human toxicity (13) . The investigators also examined canine models and found that PPV and PLR for human toxicity were not correlated with 1 another: NLR were low, indicating that the dog provided little evidentiary weight to ruling out toxicity in humans (52) . Later analysis of 3,000 drugs found that tests inferring no toxicity in any 1 species, including nonhuman primates, have no evidentiary weight with regard to toxicity in any other species (14) . In a comparison study reported by pharmaceutical companies of 150 drugs associated with adverse events or toxicity in humans (55), LR
could not be determined due to a lack of specificity reporting on the tests. Paglialunga et al. (56) examined translatability of respiratory safety pharmacology studies from animal models to humans and found that PPV and PLR were so low that animal tests provided little value in predicting human toxicity.
GROWING SCIENTIFIC CRITICISM
As early as 1962, scientists questioned the assumption that animal models reliably predicted human responses. Lichtfield (57) examined 6 drugs studied in animal models and found that rats and dogs demon- propose that it may simply be scientifically invalid to assume that toxicity of a substance in any one species can reliably predict toxicity in any other, no matter how stringent animal testing standards are made (69) .
ALTERNATIVES TO ANIMAL TESTING
Alternatives to animal testing will be discussed in more detail in part 2 of this review; they include Methodological: Animal models should be abandoned because the scientific methodology of the experiment was poor.
The quality of methodology in an individual experiment cannot be extrapolated to the question of whether animal experimentation as a whole is invalid, merely to whether the individual experiment is yielding true results.
Historical: Historically, medical dependence on animal modeling is much less robust than we are led to believe.
Historical use of animal modeling is a poor measure of the validity of current experimentation and methods. To determine whether animal modeling is reliable in current science, we need to use modern scientific knowledge and examine modern methodology to determine whether animal modeling is predictive of human outcomes today. This takes into account information and methods that may or may not have been historically available.
Reviews: Review articles have determined that certain animal species have not been critical in various medical developments, and therefore animal experimentation should be abolished.
The invalidity of using certain specific animals does not necessarily rule out animal models as a whole.
Alternatives: The existence of alternative models requires us to abandon animal research.
Whereas alternatives to animal research exist or are developing in many areas of medical research, in many instances such alternatives do not exist. This argument does not address whether continued use of animal models is scientifically valid, regardless of alternative methods, and it does not attempt to define whether certain animal models are predictably successful and others are predictably unsuccessful.
integrating predictive toxicology methods into safety and risk assessments by the FDA (86) . At this time, the FDA generally still requires submission of preclinical animal data in investigational new drug applications (5).
CONCLUSIONS
Although animal toxicity testing has been the stal- 
